Search clinical trials for: Trivalent Vaccine

Total 9978 results

Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

Neoplasms

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Influenza

Sweden
University of Witwatersrand, South Africa
University of Colorado, Denver; Emory University; Bill and Melinda Gates Foundation

Completed

Influenza Vaccine Trial in HIV Uninfected Pregnant Women (MatfluHIVneg)

Influenza

South Africa
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Influenza

Taiwan
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Central Nervous System Neoplasm

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors

Central Nervous System Neoplasm

United States
Seqirus

Completed

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Influenza, Human

United Kingdom
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Influenza

Czechia
GlaxoSmithKline

Completed

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 1, 2009

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

Dengue

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
University of Copenhagen

Unknown

cAMP Signaling and Muscle Adaptations

Muscle Hypertrophy in Healthy Young Men

Denmark
University of Michigan
American College of Allergy, Asthma and Immunology

Completed

Safe Administration of Flu Vaccine to Egg Allergic Children (SAFE)

Egg Allergy

United States
Kaiser Permanente
Centers for Disease Control and Prevention

Completed

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (FluMist)

Healthy | Influenza

United States
International Centre for Diarrhoeal Disease Research...
Johns Hopkins University; Centers for Disease Control and Prevention

Completed

Flu Vaccine Against Childhood Pneumonia, Bangladesh

Pneumonia | Laboratory Confirmed Influenza

Bangladesh
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
MedImmune LLC

Completed

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Healthy

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

Influenza, Human

United States
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Influenza
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

Influenza

Guatemala
National Institute of Allergy and Infectious Diseases...
Atopic Dermatitis Research Network

Completed

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

Dermatitis, Atopic

United States
University of Colorado, Denver
University of Alabama at Birmingham; All India Institute of Medical Sciences... and other collaborators

Completed

Influenza Immunization of Children in India

Influenza

India
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

Influenza

Mexico
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
Massachusetts General Hospital

Completed

Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine

Healthy | Elderly

United States
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Abbott

Completed

Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Australia
Novartis Vaccines

Completed

Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

FLU

Finland
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Seasonal Influenza, Vaccine

Germany
Novartis Vaccines

Completed

Immunogenicity and Safety of V70P5 Revaccination Subjects

Influenza

Finland
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (FluMist)

Healthy | Influenza

United States

3

Subscribe